EUVIMEDEUVIMED entdecken
Metaanalyse

The association between clinical trial participation, drug costs, and performance in the Oncology Care Model

Maureen E Canavan iD, Sarah Westvold iD, Valerie Csik iD, Jeffrey Franks, Gabrielle Rocque iD, Cary P Gross iD, Kerin B Adelson iD

JNCI: Journal of the National Cancer Institute · 2025

DOI: 10.1093/jnci/djaf008 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2025. Verfasst von Maureen E Canavan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Yale Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale School of Medicine, New Haven, CT 06520, United States. Hauptthemen laut MEDLINE: Clinical Trials as Topic, Medicare, Drug Costs, Neoplasms. Die Arbeit nennt 8 Literaturangaben. Gefördert von: NCCN Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

It has long been assumed that academic oncology practices are disadvantaged in value-based payment programs because of patient complexity and research costs. This assumption has not been tested. The Oncology Care Model (OCM) was a Medicare alternative payment model, which sought to curb costs while improving care. We assessed the impact of clinical trial participation on 2 outcomes: (1) cost and (2) practice performance among 3 participating National Cancer Institute–designated cancer centers using a random effects meta-analysis. The mean total Medicare cost per episode was $42 225 for clinical trial episodes and $34 937 for nonclinical trial episodes. Despite higher total costs, clinical trial episodes were more likely to be under spending targets than non–clinical trial episodes (odds ratio = 0.37, 95% confidence interval = 0.25 to 0.48). Drug costs in clinical trial episodes were lower than in nonclinical trial episodes, although this was only statistically significant at the largest volume practice. In conclusion, clinical trials may offer an advantage in value-based programs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials as TopicMedicareDrug CostsNeoplasmsMedical OncologyCancer Care FacilitiesAntineoplastic AgentsHumansUnited StatesOdds Ratio

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Yale Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale School of Medicine, New Haven, CT 06520, United States.
  • Sidney Kimmel Cancer Center Jefferson Health, Philadelphia, PA 19107, United States.
  • Department of Medicine Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL 35233, United States.
  • O'Neal Comprehensive Cancer Center, Birmingham, AL 35294, United States.
  • MD Anderson Cancer Center, Houston, TX 77030, United States.

ORCID-Profile: Maureen E Canavan, Sarah Westvold, Valerie Csik, Gabrielle Rocque, Cary P Gross, Kerin B Adelson

Förderung

  • NCCN Foundation

Zitieren

APA

Canavan, M. E., Westvold, S., Csik, V., Franks, J., Rocque, G., Gross, C. P., & Adelson, K. B. (2025). The association between clinical trial participation, drug costs, and performance in the Oncology Care Model. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djaf008

Vancouver

Canavan ME, Westvold S, Csik V, Franks J, Rocque G, Gross CP, et al. The association between clinical trial participation, drug costs, and performance in the Oncology Care Model. JNCI: Journal of the National Cancer Institute. 2025. doi:10.1093/jnci/djaf008

BibTeX
@article{Canavan2025,
  author = {Canavan, Maureen E and Westvold, Sarah and Csik, Valerie and Franks, Jeffrey and Rocque, Gabrielle and Gross, Cary P and Adelson, Kerin B},
  title = {The association between clinical trial participation, drug costs, and performance in the Oncology Care Model},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2025},
  doi = {10.1093/jnci/djaf008}
}
Kostenlos starten →